Bronchiectasis and COPD

Chronic Obstructive Pulmonary Disease

Volumn , Issue , 2008, Pages 139-147

  Wilson, Robert ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Bronchiectasis; Inflammatory cascades; Lung function tests; Mycobacteria; Pathology

Indexed keywords

EID: 84889610910     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470755976.ch12     Document Type: Chapter

References (60)

1. Wilson R. Bronchiectasis. In: Gibson GJ, Geddes DM, Costabel U, Sterk PJ, Corrin B, eds. Respiratory Medicine, vol. 2, 3rd edn. Saunders/Elsevier Science, 2003:1445-64.
2. O'Leary CJ, Wilson CB, Hansell DM et al. Relationship between psychological well-being and lung health status in patients with bronchiectasis. Respir Med 2002;96:686-92.
3. Wilson CB, Jones PW, O'Leary CJ et al. Health status assessment in bronchiectasis using the St George's Respiratory Questionnaire. Am J Respir Crit Care Med 1997;156;536-41.
4. Wilson CB, Jones PW, O'Leary CJ et al. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J 1998;12:820-4.
5. Wilson CB, Jones PW, O'Leary CJ et al. Systemic markers of inflammation in stable bronchiectasis. Eur Respir J 1998;12:820-4.
6. Seemungal TAR, Donaldson GC, Bhowmik A et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608-13.
7. Cole PJ. Bronchiectasis. In: Brewis RAL, Corrin B, Geddes AM, Gibson GJ, eds. Respiratory Medicine, 2nd edn. London: WB Saunders, 1995:1286-317.
8. Lapae Silva JR, Jones JAH, Cole PJ, Poulter PW. The immunological component of the cellular inflammatory infiltrate in bronchiectasis. Thorax 1989;44:668-73.
9. Zheng L, Tipoe G, Lam WK et al. Upregulation of circulating adhesion molecules in bronchiectasis. Eur Respir J 2000;16:691-6.
10. Wilson R, Dowling R, Jackson AD. The biology of bacterial colonization and invasion of the respiratory mucosa. Eur Respir J 1996;9:523-30.
11. Monso E, Ruiz J, Rosell A et al. Bacterial infection in chronic obstructive pulmonary disease: a study of stable and exacerbated patients using the protected specimen brush. Am J Respir Crit Care Med 1995;152:1316-20.
12. Sethi S, Evans N, Brydon JB, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002;347:465-71.
13. Wilson R. Bacterial infection and chronic obstructive pulmonary disease. Eur Respir J 1999;13:233-5.
14. Soler N, Eurig S, Torres A et al. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J 1999;14:1015-22.
15. Patel IS, Seemungal TAR, Wilks M et al. Relationship between bacterial colonisation and the frequency, character and severity of COPD exacerbations. Thorax 2002;57:759-64.
16. Donaldson GC, Seemungal TAR, Bhomik A, Wedzicha JA. The relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-52.
17. Vernooy J, Dentener MA, Vam Smylen RJ, Buurman WA, Wouters EM. Long term intratracheal lipopolysaccharide exposure in mice results in chronic lung inflammation and persistent pathology. Am J Respir Cell Mol Biol 2002;26:152-9.
18. Wilkinson TMA, Patel IS, Wilks M, Donaldson GC, Wedzicha JA. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167:1090-5.
19. Hill AT, Campbell EJ, Hill SL et al. Association between airway bacterial load and markers of inflammatory in patients with stable chronic bronchiectasis. Am J Med 2000;109:288-95.
20. Wilson R. The pathogenesis and management of bronchial infections: the vicious circle of respiratory decline. Rev Contemp Pharacother 1992;3:103-12.
21. Eller J, Ede A, Schaberg T et al. Infective exacerbations of chronic bronchitis: relationship between bacteriological aetiology and lung function. Chest 1998;113:1542-8.
22. Miravitlles M, Espinosa C, Fernandez-Laso E et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest 1999;115:40-6.
23. Soler N, Torres A, Eurig S et al. Bronchial microbial pattersn in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998;157:1498-1505.
24. Wells CT, Miszkiel KA, Wells AU et al. Effects of airway infection by Pseudomonas aeruginosa: a computed tomography study. Thorax 1997;52:260-4.
25. Pasteur MC, Helliwell S, Houghton SJ et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000;162:1277-84.
26. Curry DC, Cooke JC, Morgan AD et al. Interpretation of bronchograms and chest radiographs in patients with chronic sputum production. Thorax 1987;42:278.
27. Reiff DB, Wells AU, Carr DH et al. CT findings in bronchiectasis: limited value in distinguishing between idiopathic and specific types. Am J Roentgenol 1995;165:261-7.
28. Engeler CE, Tashijian JH, Engeler CM et al. Volumetric highresolution CT in the diagnosis of interstitial lung disease and bronchiectasis: diagnostic accuracy and radiation dose. Am J Roentgenol 1994;163:31-5.
29. Mawdsley S, Nash K et al. Staphylococcus aureus in patients with bronchiectasis: identification of disease associations. Eur Respir J 1998;12:1340-4.
30. Biederer J, Both M, Graessner J et al. Lung morphology: fast MR imaging assessment with volumetric interpolated breathhold technique-initial experience with patients. Radiology 2003;226:242-9.
31. Munro NC, Cooke JC, Currie DC, Strickland B, Cole PJ. Comparison of thin-section computed tomography with bronchography for identifying bronchiectatic segments in patients with chronic sputum production. Thorax 1990;45:135-9.
32. Seemungal TAR, Donaldson GC, Paul EA et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-22.
33. Vesto J, Prescott E, Longe P. Association between chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Am J Respir Crit Care Med 1996;153:1530-5.
34. Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J 1995;8:1333-8.
35. O'Brien C, Guest PJ, Hill SH et al. Physiological and radiological characterisation of patient diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000;55:635-42.
36. Patel IS, Vlahos I, Wilkinson TMA et al. Bronchiectasis, exacerbation indices and inflammation in COPD. Am J Respir Crit Care Med 2004;170:400-7.
37. Wilson R, Schentag JJ, Ball P, Mandell L. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long term outcomes. Clin Ther 2002;24:639-52.
38. Wilson R, Allegra L, Huchon G et al. Short and long term outcomes of moxifloxacin in acute exacerbations of chronic bronchitis. Chest 2004;125:953-64.
39. Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:358-64.
40. Bhowmik A, Seemungal TAR, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000;55:114-20.
41. Sheehan RE, Wells AU, Copley SJ et al. A comparison of serial computed tomography and functional change in bronchiectasis. Eur Respir J 2002;20:581-7.
42. Wells A, Rahman A, Woodhead M et al. Voluntary cough suppression associated with chronic pulmonary suppuration: a new syndrome. Eur Respir J 1992;5(Suppl 15):141S.
43. Tsang KWT, Ho PL, Lam WK et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. Am J Respir Crit Care Med 1998;158:723-7.
44. Stevens DA, Schwartz HJ, Lee JY et al. A randomised trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 2000;342:756-62.
45. O'Donnell AE, Barker AF, Howke JS, Fick RB. Treatment of idiopathic bronchiectasis with recombinant human DNase. Chest 1998;113:1329-34.
46. Grascouin A, Desrues B, Lena H et al. Long term nasal intermittent positive pressure ventilation (NIPPV) in sixteen consecutive patients with bronchiectasis: a retrospective study. Eur Respir J 1996;9:1246-50.
47. Monso E, Rosell AI, Boret G et al. Risk factors of lower airway bacterial colonisation in chronic bronchitis. Eur Respir J 1999;13:338-42.
48. Zalacain R, Sobradillo V, Anilibia J et al. Predisposing factors to bacterial colonisation in chronic obstructive pulmonary disease. Eur Respir J 1999;13:348-8.
49. Soler N, Ewig S, Torres A et al. Airway inflammation and bronchial microbial patters in patients with stable chronic obstructive pulmonary disease. Eur Respir J 1999;14:1015-22.
50. Murphy TF, Sethi S, Klingman KL et al. Simultaneous respiratory tract colonization by multiple strains of non-typable Haemophilus influenzae in chronic obstructive pulmonary disease: implications for antibiotic therapy. J Infect Dis 1999;180:404-9.
51. Bresser P, van Alphen L, Habets FJM. Persisting Haemophilus influenzae strains induce lower levels of interleukin-6 and interleukin-8 in H292 lung epithelial cells than non-persisting strains. Eur Respir J 1997;10:2319-26.
52. Angrill J, Agusti C, de Celis R et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002;57:15-9.
53. Rayner CFJ, Tillotson G, Cole PJ, Wilson R. Efficacy and safety of long term ciprofloxacin in the management of severe bronchiectasis. J Antimicrob Chemother 1994;34:149-56.
54. Mukopadhyay S, Singh M, Cater J et al. Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks. Thorax 1996;51:364-8.
55. Szaff M, Hoiby N, Flensborg EW. Frequent antibiotic therapy improves survical of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand 1983;72:651-7.
56. Elborn JS, Prescott RJ, Stack BHR et al. Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs. Thorax 2000;55:355-8.
57. Labro MT, Abdelghaffar H. Immunomodulation by macrolide antibiotics. J Chemother 2001;13:3-8.
58. Howe RA, Spencer RC. Macrolides for the treatment of Pseudomonas aeruginosa infections? J Antimicrob Chemother 1997;40:153-5.
59. Wolter J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002;57:212-6.
60. Davies G, Wilson R. Prophylactic antibiotic treatment of bronchiectasis with azithromycin. Thorax 2004;59:540-1.